Loading
A phase 1/2 trial of T3011 high dose in advanced solid tumours, run by Shanghai Pharmaceuticals Holding Co., Ltd, now recruiting.
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06214143 by Shanghai Pharmaceuticals Holding Co., Ltd, with 68 participants planned, started 2024-01-11 and due to reach its primary completion in 2026-12-31. Interventions recorded: T3011 high dose, T3011 middle dose and T3011 low dose.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares GenFleet Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/